These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 16193303)

  • 1. Decitabine activates specific caspases downstream of p73 in myeloid leukemia.
    Tamm I; Wagner M; Schmelz K
    Ann Hematol; 2005 Dec; 84 Suppl 1():47-53. PubMed ID: 16193303
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 5-Aza-2'-deoxycytidine induces p21WAF expression by demethylation of p73 leading to p53-independent apoptosis in myeloid leukemia.
    Schmelz K; Wagner M; Dörken B; Tamm I
    Int J Cancer; 2005 May; 114(5):683-95. PubMed ID: 15609309
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TAp73 and ΔNp73 have opposing roles in 5-aza-2'-deoxycytidine-induced apoptosis in breast cancer cells.
    Lai J; Yang F; Zhang W; Wang Y; Xu J; Song W; Huang G; Gu J; Guan X
    Mol Cells; 2014 Aug; 37(8):605-12. PubMed ID: 25134538
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 5-Aza-2'-deoxycytidine increases the sensitivity of human bone marrow mesenchymal stem cells to chemotherapeutic agents by demethylation of p73.
    Liang W; Xia H; Li J; Chunhua Zhao R
    J Pediatr Hematol Oncol; 2012 Mar; 34(2):108-15. PubMed ID: 22278203
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 5-Aza-2'-deoxycytidine (decitabine) can relieve p21WAF1 repression in human acute myeloid leukemia by a mechanism involving release of histone deacetylase 1 (HDAC1) without requiring p21WAF1 promoter demethylation.
    Scott SA; Dong WF; Ichinohasama R; Hirsch C; Sheridan D; Sanche SE; Geyer CR; Decoteau JF
    Leuk Res; 2006 Jan; 30(1):69-76. PubMed ID: 16043219
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of genome-wide methylation and gene expression induced by 5-aza-2'-deoxycytidine identifies BCL2L10 as a frequent methylation target in acute myeloid leukemia.
    Fabiani E; Leone G; Giachelia M; D'alo' F; Greco M; Criscuolo M; Guidi F; Rutella S; Hohaus S; Voso MT
    Leuk Lymphoma; 2010 Dec; 51(12):2275-84. PubMed ID: 21077739
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activation of expression of p15, p73 and E-cadherin in leukemic cells by different concentrations of 5-aza-2'-deoxycytidine (Decitabine).
    Farinha NJ; Shaker S; Lemaire M; Momparler L; Bernstein M; Momparler RL
    Anticancer Res; 2004; 24(1):75-8. PubMed ID: 15015578
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Smac mimetic and demethylating agents synergistically trigger cell death in acute myeloid leukemia cells and overcome apoptosis resistance by inducing necroptosis.
    Steinhart L; Belz K; Fulda S
    Cell Death Dis; 2013 Sep; 4(9):e802. PubMed ID: 24030154
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Decitabine induces delayed reactive oxygen species (ROS) accumulation in leukemia cells and induces the expression of ROS generating enzymes.
    Fandy TE; Jiemjit A; Thakar M; Rhoden P; Suarez L; Gore SD
    Clin Cancer Res; 2014 Mar; 20(5):1249-58. PubMed ID: 24423613
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Decitabine induces cell cycle arrest at the G1 phase via p21(WAF1) and the G2/M phase via the p38 MAP kinase pathway.
    Lavelle D; DeSimone J; Hankewych M; Kousnetzova T; Chen YH
    Leuk Res; 2003 Nov; 27(11):999-1007. PubMed ID: 12859993
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The DNA demethylating agent decitabine activates the TRAIL pathway and induces apoptosis in acute myeloid leukemia.
    Soncini M; Santoro F; Gutierrez A; Frigè G; Romanenghi M; Botrugno OA; Pallavicini I; Pelicci P; Di Croce L; Minucci S
    Biochim Biophys Acta; 2013 Jan; 1832(1):114-20. PubMed ID: 23046813
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The C/EBPdelta tumor suppressor is silenced by hypermethylation in acute myeloid leukemia.
    Agrawal S; Hofmann WK; Tidow N; Ehrich M; van den Boom D; Koschmieder S; Berdel WE; Serve H; Müller-Tidow C
    Blood; 2007 May; 109(9):3895-905. PubMed ID: 17234736
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential TERT promoter methylation and response to 5-aza-2'-deoxycytidine in acute myeloid leukemia cell lines: TERT expression, telomerase activity, telomere length, and cell death.
    Pettigrew KA; Armstrong RN; Colyer HA; Zhang SD; Rea IM; Jones RE; Baird DM; Mills KI
    Genes Chromosomes Cancer; 2012 Aug; 51(8):768-80. PubMed ID: 22517724
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines.
    Hollenbach PW; Nguyen AN; Brady H; Williams M; Ning Y; Richard N; Krushel L; Aukerman SL; Heise C; MacBeth KJ
    PLoS One; 2010 Feb; 5(2):e9001. PubMed ID: 20126405
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SMG1 acts as a novel potential tumor suppressor with epigenetic inactivation in acute myeloid leukemia.
    Du Y; Lu F; Li P; Ye J; Ji M; Ma D; Ji C
    Int J Mol Sci; 2014 Sep; 15(9):17065-76. PubMed ID: 25257528
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decitabine has a biphasic effect on natural killer cell viability, phenotype, and function under proliferative conditions.
    Kopp LM; Ray A; Denman CJ; Senyukov VS; Somanchi SS; Zhu S; Lee DA
    Mol Immunol; 2013 Jul; 54(3-4):296-301. PubMed ID: 23328088
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Decitabine, a DNA methyltransferases inhibitor, induces cell cycle arrest at G2/M phase through p53-independent pathway in human cancer cells.
    Shin DY; Sung Kang H; Kim GY; Kim WJ; Yoo YH; Choi YH
    Biomed Pharmacother; 2013 May; 67(4):305-11. PubMed ID: 23582784
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Digging deep into "dirty" drugs - modulation of the methylation machinery.
    Pleyer L; Greil R
    Drug Metab Rev; 2015 May; 47(2):252-79. PubMed ID: 25566693
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increasing TIMP3 expression by hypomethylating agents diminishes soluble MICA, MICB and ULBP2 shedding in acute myeloid leukemia, facilitating NK cell-mediated immune recognition.
    Raneros AB; Minguela A; Rodriguez RM; Colado E; Bernal T; Anguita E; Mogorron AV; Gil AC; Vidal-Castiñeira JR; Márquez-Kisinousky L; Bulnes PD; Marin AM; Garay MCG; Suarez-Alvarez B; Lopez-Larrea C
    Oncotarget; 2017 May; 8(19):31959-31976. PubMed ID: 28404876
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of tumour-specific epigenetic events in medulloblastoma development by hypermethylation profiling.
    Lindsey JC; Lusher ME; Anderton JA; Bailey S; Gilbertson RJ; Pearson AD; Ellison DW; Clifford SC
    Carcinogenesis; 2004 May; 25(5):661-8. PubMed ID: 14688019
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.